Back

Mesenchymal stroma cell-derived stem cell factor mediates cross-species compatibility of the hematopoietic stem cell niche.

Froebel, J.; Rahmig, S.; Metz, J.; Kucinski, I.; Svensson, C.-M.; Reinhardt, S.; Salbach-Hirsch, J.; Coppin, E.; Mende, N.; Henning, N.; Percin, G. I.; Weschenfelder, F.; Koehler, A.; Platz, A.; Gottgens, B.; Rauner, M.; Figge, M. T.; Hoefer, T.; Dahl, A.; Waskow, C.

2026-05-04 cell biology
10.64898/2026.04.30.719914 bioRxiv
Show abstract

The regulation of human hematopoietic stem cell (HSC) function through its native environment is virtually unknown. Cross-species chimeras, particularly humanized mice, are essential tools for investigating human HSC function in vivo. However, conventional models often require toxic conditioning that impairs niche and donor cell function, or simplify niche complexity. We utilize NSGW41 mice, which harbor a KIT receptor mutation, to achieve robust human leukocyte engraftment without prior treatment. We demonstrate that KIT-proficient human HSCs possess a clear advantage, effectively outcompeting endogenous murine stem cells and progenitors to establish stable, multilineage human hematopoiesis. Crucially, the murine niche undergoes significant plastic adaptation in response to humanization. We identify that mesenchymal stromal cells (MSCs) expand and undergo a transcriptional shift, transitioning from a mixed adipo- or osteo-primed state toward predominantly Lepr+ adipo-primed HSC-supporting cells. This adaptation is vital; the depletion of Lepr+ MSCs or the targeted deletion of Stem Cell Factor (SCF) from these cells leads to the mobilization or loss of human HSC engraftment, respectively. These findings provide compelling evidence for functional cross-species niche-HSC communication, identifying Lepr+MSCs as primary regulators of human HSC maintenance in xenotransplantation models. By mapping this molecular dialogue, our work establishes a physiological in vivo platform to study human HSC biology and evaluate niche-targeted therapeutic interventions to improve transplantation outcomes.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cell Stem Cell
57 papers in training set
Top 0.1%
22.1%
2
Developmental Cell
168 papers in training set
Top 2%
9.9%
3
Nature Cell Biology
99 papers in training set
Top 0.7%
6.2%
4
Cell Reports
1338 papers in training set
Top 8%
6.2%
5
Cell
370 papers in training set
Top 5%
4.2%
6
Nature Communications
4913 papers in training set
Top 38%
3.9%
50% of probability mass above
7
Nature
575 papers in training set
Top 7%
3.5%
8
eLife
5422 papers in training set
Top 27%
3.5%
9
Molecular Cell
308 papers in training set
Top 4%
3.5%
10
Blood
67 papers in training set
Top 0.5%
3.0%
11
Journal of Experimental Medicine
106 papers in training set
Top 2%
2.0%
12
Science
429 papers in training set
Top 15%
1.7%
13
Cell Systems
167 papers in training set
Top 7%
1.7%
14
Cancer Discovery
61 papers in training set
Top 1%
1.7%
15
Protein & Cell
25 papers in training set
Top 1%
1.5%
16
Cell Research
49 papers in training set
Top 1%
1.5%
17
Advanced Science
249 papers in training set
Top 14%
1.3%
18
Cell Discovery
54 papers in training set
Top 3%
1.3%
19
Science Advances
1098 papers in training set
Top 22%
1.3%
20
Cell Metabolism
49 papers in training set
Top 2%
1.2%
21
Immunity
58 papers in training set
Top 3%
1.1%
22
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
23
JCI Insight
241 papers in training set
Top 6%
0.9%
24
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 42%
0.9%
25
Nature Immunology
71 papers in training set
Top 2%
0.8%
26
Nucleic Acids Research
1128 papers in training set
Top 18%
0.7%
27
PLOS Biology
408 papers in training set
Top 20%
0.7%
28
Nature Medicine
117 papers in training set
Top 5%
0.7%
29
Stem Cell Reports
118 papers in training set
Top 1%
0.7%
30
The EMBO Journal
267 papers in training set
Top 7%
0.6%